Timing of Tocilizumab Use and COVID-19

References

1. 1.↵
   1. Singh AK,
   2. Oks M,
   3. Husk G,
   4. Dechario SP,
   5. Mina B,
   6. Singh K,
   7. et al

   . Impact of timing of tocilizumab use in hospitalized patients with SARS-CoV-2 infection. Respir Care 2021;66(12):1805-1814.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Adil A,
   2. Sobani ZA,
   3. Jabbar A,
   4. Adil SN,
   5. Awan S

   . Endocrine complications in patients of beta thalassemia major in a tertiary care hospital in Pakistan. J Pak Med Assoc 2012;62(3):307-310.

   OpenUrlPubMed
3. 3.↵
   1. Miller JL

   . Iron deficiency anemia: a common and curable disease. Cold Spring Harb Perspect Med 2013;3(7):a011866-a011866.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Jehn M,
   2. Clark JM,
   3. Guallar E

   . Serum ferritin and risk of the metabolic syndrome in US adults. Diabetes Care 2004;27(10):2422-2428.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Brosnahan SB,
   2. Chen XJC,
   3. Chung J,
   4. Altshuler D,
   5. Islam S,
   6. Thomas SV,
   7. et al

   . Low-dose tocilizumab with high-dose corticosteroids in patients hospitalized for COVID-19 hypoxic respiratory failure improves mortality without increased infection risk. Ann Pharmacother 2021:106002802110288. 10600280211028882.
6. 6.↵
   1. Milic J,
   2. Banchelli F,
   3. Meschiari M,
   4. Franceschini E,
   5. Ciusa G,
   6. Gozzi L,
   7. et al

   . The impact of tocilizumab on respiratory support states transition and clinical outcomes in COVID-19 patients. A Markov model multi-state study. PLoS One 2021;16(8):e0251378.

   OpenUrl
7. 7.↵
   1. Raja K,
   2. Daniel N,
   3. Morrison S,
   4. Patel R,
   5. Gerges J,
   6. Nadeem K,
   7. et al

   . Impact of tocilizumab on clinical outcomes in COVID-19–associated cytokine release syndrome: a single-center Experience. J Pharm Pract 20218971900211028208.